Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04898231 · ClinicalTrials.gov registry record · Phase 2
MIS-C Comparative Effectiveness Study
A Phase 2 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT04898231 is a Phase 2 study that has completed, run by University of California, San Diego. The registered enrollment target is 73 participants.
The verdict
NCT04898231, a Phase 2 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be known as Multisystem Inflammatory Syndrome-Children (MIS-C).The clinical presentation shared many features with Kawasaki disease (KD), a self-limited inflammation that can cause ballooning of the arteries of the heart. Thus, physicians reached for many of the therapies used to treat children with KD. Despite the surge of COVID-19 cases and children continuing to present with MIS-C, there are no data that guide the choice of therapy. Thus, the investigators have designed a study to determine which combination of therapies is most effective in helping children with MIS-C recover quickly.
Interventions
- DRUG Methylprednisolone
- DRUG Infliximab
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2024-04-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04898231
The ClinicalTrials.gov registry entry for NCT04898231 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Methylprednisolone is the first listed.
NCT04898231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04898231 about?
NCT04898231 is a clinical study titled "MIS-C Comparative Effectiveness Study". In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus. Some children were sick enough to require care in the intensive care unit for what came to be known as Multisystem I...
What is the current status of trial NCT04898231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2020-12-22. Estimated completion is 2024-04-25.
What interventions are being tested in trial NCT04898231?
The interventions under investigation include: Methylprednisolone (DRUG), Infliximab (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT04898231?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.